

Emilia Modolo Pinto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/271148/publications.pdf>

Version: 2024-02-01

53
papers

1,566
citations

279487

23
h-index

315357

38
g-index

59
all docs

59
docs citations

59
times ranked

2053
citing authors

#	ARTICLE	IF	CITATIONS
1	An Inherited Mutation Outside the Highly Conserved DNA-Binding Domain of the p53 Tumor Suppressor Protein in Children and Adults with Sporadic Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4970-4973.	1.8	183
2	Genomic landscape of paediatric adrenocortical tumours. <i>Nature Communications</i> , 2015, 6, 6302.	5.8	166
3	Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2004, 48, 647-650.	1.3	109
4	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 37-43.	1.6	103
5	Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. <i>Pituitary</i> , 2009, 12, 297-303.	1.6	65
6	Three Novel Mutations in CYP21 Gene in Brazilian Patients with the Classical Form of 21-Hydroxylase Deficiency Due to a Founder Effect. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4314-4317.	1.8	57
7	CLASSICAL OSTEOLASTOMA, ATYPICAL OSTEOLASTOMA, AND OSTEOSARCOMA. A COMPARATIVE STUDY BASED ON CLINICAL, HISTOLOGICAL, AND BIOLOGICAL PARAMETERS. <i>Clinics</i> , 2007, 62, 167-174.	0.6	50
8	Evaluating the Roles of Follicle-Stimulating Hormone Receptor Polymorphisms in Gonadal Hyperstimulation Associated with Severe Juvenile Primary Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2312-2317.	1.8	46
9	An update on the central nervous system manifestations of Liê€Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2020, 139, 669-687.	3.9	44
10	Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 826-830.	1.8	42
11	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 2463-2473.	0.8	38
12	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
13	Deletion Mapping of Chromosome 17 in Benign and Malignant Adrenocortical Tumors Associated with the Arg337His Mutation of the p53 Tumor Suppressor Protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2976-2981.	1.8	34
14	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Childrenâ€™s Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3956-3963.	0.8	33
15	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. <i>Cancer Research</i> , 2020, 80, 3732-3744.	0.4	32
16	Molecular analysis of <i>CYP21A2</i> can optimize the followâ€™up of positive results in newborn screening for congenital adrenal hyperplasia. <i>Clinical Genetics</i> , 2009, 76, 503-510.	1.0	30
17	Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 477-490.	2.2	30
18	TP53-Associated Pediatric Malignancies. <i>Genes and Cancer</i> , 2011, 2, 485-490.	0.6	30

#	ARTICLE	IF	CITATIONS
19	What 20 years of research has taught us about the <i>TP53</i> p.R337H mutation. <i>Cancer</i> , 2020, 126, 4678-4686.	2.0	30
20	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. <i>Clinical Cancer Research</i> , 2013, 19, 1740-1747.	3.2	29
21	Pediatric adrenocortical tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101448.	2.2	29
22	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. <i>Nature Communications</i> , 2019, 10, 5806.	5.8	27
23	The degree of external genitalia virilization in girls with 21â€hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. <i>Clinical Endocrinology</i> , 2008, 68, 226-232.	1.2	26
24	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	3.9	26
25	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2016, 22, 6247-6255.	3.2	22
26	The E180splice mutation in the <i>GHR</i> gene causing Laron syndrome: Witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World?. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 1204-1208.	0.7	19
27	Possible role of a radiation-induced p53 mutation in a Nelsonâ€™s syndrome patient with a fatal outcome. <i>Pituitary</i> , 2011, 14, 400-404.	1.6	18
28	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. <i>Cancers</i> , 2020, 12, 506.	1.7	17
29	ABO genotyping in leukemia patients reveals new ABO variant alleles. <i>Genetics and Molecular Research</i> , 2008, 7, 87-94.	0.3	16
30	Contemporary preclinical human models of adrenocortical carcinoma. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 139-144.	0.6	15
31	Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. <i>Familial Cancer</i> , 2011, 10, 141-146.	0.9	13
32	Cryptic intragenic deletion of the SHOX gene in a family with LÃ©ri-Weill dyschondrosteosis detected by Multiplex Ligation-Dependent Probe Amplification (MLPA). <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2008, 52, 1382-1387.	1.3	9
33	The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. <i>Cancer Research</i> , 2021, 81, 2442-2456.	0.4	9
34	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. <i>British Journal of Cancer</i> , 2020, 122, 1231-1241.	2.9	8
35	Congenital Hyperinsulinism in Brazilian Neonates: A Study of Histology, KATP Channel Genes, and Proliferation of Î² Cells. <i>Pediatric and Developmental Pathology</i> , 2010, 13, 375-384.	0.5	7
36	Differential elemental distribution of retained particles along the respiratory tract. <i>Inhalation Toxicology</i> , 2011, 23, 459-467.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1159-1169.	1.8	7
38	Population Genetics of Nine Short Tandem Repeat Loci. American Journal of Forensic Medicine and Pathology, 2002, 23, 186-190.	0.4	6
39	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precision Oncology, 2019, 3, 1-21.	1.5	6
40	Glucose-dependent insulintropic peptide receptor overexpression in adrenocortical hyperplasia in MEN1 syndrome without loss of heterozygosity at the 11q13 locus. Clinics, 2011, 66, 529-33.	0.6	6
41	iASPP: A Novel Protein Involved in Pituitary Tumorigenesis?. Frontiers of Hormone Research, 2010, 38, 70-76.	1.0	5
42	Children with Cushing's syndrome: primary pigmented nodular adrenocortical disease should always be suspected. Pituitary, 2011, 14, 61-67.	1.6	5
43	Maternal isodisomy causing homozygosity for a dominant activating mutation of the luteinizing hormone receptor gene in a boy with familial male-limited precocious puberty. Clinical Endocrinology, 2003, 59, 533-534.	1.2	4
44	From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Journal of Physical Education and Sports Management, 2019, 5, a003921.	0.5	4
45	Clinical and Functional Significance of TP53 Exon 4 Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
46	An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers. Oncogenesis, 2012, 1, e1-e1.	2.1	3
47	Insulin-like growth factor 1 gene (CA) _n repeats and a variable number of tandem repeats of the insulin gene in Brazilian children born small for gestational age. Clinics, 2013, 68, 785-791.	0.6	3
48	TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC. Cancers, 2022, 14, 1655.	1.7	3
49	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. Frontiers in Endocrinology, 2021, 12, 756523.	1.5	2
50	Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers. Cancers, 2022, 14, 3014.	1.7	1
51	KDM6B Inhibition Has Anti-Tumor Activity in Anaplastic Wilms Tumor Cells Associated with WT1 And MYCN Pathway Silencing. , 2021, , .		0
52	Pathogenesis of Adrenocortical Tumors. , 2010, , 41-52.		0
53	Abstract 4889: Characterizing the viromes in pediatric cancers through whole genome sequencing. , 2017, , .		0